首页> 外文期刊>Annals of the New York Academy of Sciences >Pathology of Pheochromocytoma and Extra-adrenal Paraganglioma
【24h】

Pathology of Pheochromocytoma and Extra-adrenal Paraganglioma

机译:嗜铬细胞瘤和肾上腺旁神经节瘤的病理学

获取原文
获取原文并翻译 | 示例
           

摘要

The 2004 WHO classification of endocrine tumors defines pheochromocytoma as a tumor arising from chromaffin cells in the adrenal medulla. Closely related tumors in extra-adrenal sympathetic and parasympathetic paraganglia are classified as extra-adrenal paragangliomas. A pheochromocytoma is an intra-adrenal sympathetic paraganglioma. While arbitrary, this nomenclature serves to emphasize important distinctive properties of intra-adrenal tumors that must be taken into account in clinical practice and research. Those include an often adrenergic phenotype, a relatively low rate of malignancy, and a predilection to occur in particular hereditary syndromes. Current roles of pathology are limited to distinguishing primary or metastatic pheochromocy-tomas/paragangliomas from other endocrine or nonendocrine tumors, and flagging tumors that show features suggestive of malignant potential or syndromic disease. Future roles may involve more definitive assessment of malignancy, genotype-phenotype correlation, and identification of targets for therapy. Pathology practice currently rests mostly on interpretation of conventional histological sections stained with hematoxylin and eosin, with variable ancillary application of immunohistochemical staining. Malignancy is currently defined by the presence of metastases, not local invasion. Local invasion alone is a poor predictor of metastases, and the absence of apparent invasion does not preclude development of metastases. The two types of aggressive behavior might therefore have different biological underpinnings, and those will be resolved most effectively if consistent terminology is employed. In order to be optimally informative, pathology reports must employ consistent nomenclature and incorporate standard elements. Templates or checklists for minimal standard reporting are recommended by several pathology associations, but identification of some recommended and optional elements is currently subjective or inconsistent.
机译:2004年WHO对内分泌肿瘤的分类将嗜铬细胞瘤定义为肾上腺髓质中嗜铬细胞引起的肿瘤。肾上腺交感神经节和副交感神经旁神经节的密切相关的肿瘤被归类为肾上腺神经节旁神经瘤。嗜铬细胞瘤是肾上腺内交感神经节旁瘤。尽管是随意的,但该命名法旨在强调肾上腺内肿瘤的重要独特特性,这在临床实践和研究中必须予以考虑。这些包括经常的肾上腺素能表型,相对较低的恶性率以及在特定的遗传综合征中的发生倾向。病理学的当前作用仅限于将原发性或转移性嗜铬细胞瘤/副神经节瘤与其他内分泌或非内分泌肿瘤区分开,并标记表现出提示潜在恶性或综合征性疾病特征的肿瘤。未来的角色可能包括对恶性肿瘤,基因型与表型的相关性进行更确定的评估,以及确定治疗靶标。目前,病理学实践主要取决于对苏木精和曙红染色的常规组织切片的解释,以及免疫组织化学染色的各种辅助应用。目前,恶性肿瘤是由转移的存在而不是局部浸润来定义的。仅局部浸润不能很好地预测转移,并且没有明显浸润并不排除转移的发生。因此,这两种类型的攻击行为可能具有不同的生物学基础,如果采用一致的术语,则将最有效地解决这些问题。为了提供最佳信息,病理报告必须采用一致的术语并结合标准元素。几个病理学协会推荐用于最小标准报告的模板或清单,但是目前对某些推荐和可选元素的识别是主观的或不一致的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号